Loss of p16 expression is a sensitive marker of CDKN2A homozygous deletion in malignant meningiomas is a research paper published in Acta Neuropathologica (2023). On theSindex it has a DataRank of 0.483. It has been cited 24 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.483
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →NIH Office of the Director
Grant: DP5 OD021403
National Cancer Institute, NIH
Grant: T32 CA151022
NCI NIH HHS
Grant: R01 CA262311
National Institutes of Health
Grant: 1DP5OD021403-01
Cohesin gene mutations in tumorigenesis
National Institutes of Health
Grant: 5T32CA151022-07
Training Program in Translational Brain Tumor Research
FWCI
4.37
Citation Percentile
1.0%
Influential Citations
1
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Additional file 1 of P16 immunohistochemistry is a sensitive and specific surrogate marker for CDKN2A homozygous deletion in gliomas
Additional file 1 of P16 immunohistochemistry is a sensitive and specific surrogate marker for CDKN2A homozygous deletion in gliomas